Tumor antigen presentation: Changing the rules

Cancer Immunology Immunotherapy

Volumn 46, Issue 2, 1998, Pages 70-74

  Armstrong, Todd D ^a   Pulaski, Beth A ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cell based cancer vaccines; Cross priming; Immuno herapy; MHC class II; Tumor antigen presentation

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; NEOPLASMS; TRANSFECTION;

EID: 0031967580     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050463     Document Type: Conference Paper

References (40)

1. Armstrong T, Clements V, Martin B, Ting JP-Y, Ostrand-Rosenberg S (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 120:123-128
2. + T lymphocytes. J Immunol 160:661-666
3. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619-629
4. Bevan M (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283-1288
5. Bevan M (1976) Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 117:2233-2238
6. Blankenstein T, Cayeux S, Qin Z (1996) Genetic approaches to cancer immunotherapy. Rev Physiol Biochem Pharmacol 129:1-49
7. Boczkowski D, Nair S, Snyder D, Gilboa E (1996) Dendritic cells pulsed with rNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
8. + T lymphocytes. J Immunol 152:1523-1531
9. Cayeux S, Richter G, Noffz, G, Dorken B, Blankenstein T (1997) Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 158: 2834-2841
10. Celluzzi C, Mayordoma J, Storkus W, Lotze M, Falo L Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 183:283-287
11. Chen P, Ananthaswamy H (1993) Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 151:244-255
12. De Benedette M, Chu N, Pollock K, Hurtado J, Wade W, Kwon B, Watts T (1995) Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation of M12 B lymphomas by cAMP. J Exp Med 181:985-992
13. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
14. Falo L, Kovacsovics-Bankowski M, Thompson K, Rock K (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1:649-653
15. Huang A, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
16. Huang A, Bruce A, Pardoll D, Levitsky H (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 183:769-776
17. James R, Edwards S, Hui K, Bassett P, Grosveld F (1991) The effect of class II gene transfection on the tumorigenicity of the H-2K negative mouse leukemia cell line K36.16. Immunology 72:213-218
18. Keene J, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155:768-782
19. Kern D, Klarnet J, Jensen M, Greenberg P (1986) Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 136:4303-4310
20. Lanzavecchia A (1996) Mechanisms of antigen uptake for presentation. Curr Opin Immunol 8:348-354
21. Lin K-Y, Guarnieri F, Staveley-O'Carroll K, Levitsky H, August J, Pardoll D, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26
22. Mackey M, Gunn J, Ting P, Kikutani H, Dranoff G, Noelle R, Barth R Jr (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57:2569-2574
23. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulie P, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885
24. Mukherji B, Chakraborty N, Yamasaki S, Okino T, Yamase H, Sporn J, Kurtzman S, Ergin M, Ozols J, Meehan J, Mauri F (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078-8082
25. Ostrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6:722-727
26. Ostrand-Rosenberg S, Thakur A, Clements V (1990) Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144:4068-4071
27. Paglia P, Chiodoni C, Rodolfo M, Colombo M (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322
28. Pollock K, Kim Y, Hurtado J, Shou Z, Kim K, Kwon B (1994) 4-1BB T cell antigen binds to mature B cells and macrophages and costimulates unti-mu primed splenic B cells. Eur J Immunol 24:367
29. Porgador A, Snyder D, Gilboa E (1996) Induction of anti-tumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918-2926
30. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Frelinger JG, Lord EM (1993) IL-3 enhances development of tumor-reactive cytotoxic cells by a CD4 dependent mechanism. Cancer Res 53:2112-2117
31. Pulaski B, Yeh K, Shastri N, Maltby K, Penney D, Lord E Frelinger J (1996) IL-3 enhances CTL development and class I MHC presentation of exogenous antigen by tumor-infiltrating macrophages. Proc Natl Acad Sci USA 93:3669-3674
32. Pulaski B, Ostrand-Rosenberg S (1998) MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth. Cancer Res (in press)
33. Salgaller M, Marincola F, Cormier J, Rosenberg S (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749-4757
34. Shu S, Krinock R, Matsumura T, Sussman J, Fox B, Chang A, Terman D (1994) Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152:1277-1288
35. Suto R, Srivastava P (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585-1588
36. Watts C (1997) Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15:821-850
37. Yang G, Mizuno M, Hellstrom K, Chen L (1997) B7-negative versus B7-positive P815 Tumor. Differential requirements for priming of an antitumor immune response in lymph nodes. J Immunol 158:851-858
38. Yeh K-Y, McAdam A, Pulaski B, Shastri N, Frelinger J, Lord E (1998) IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatiblity antigen and generation of primary tumor specific cytolytic T lymphocytes. (in press)
39. York I, Rock K (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369-396
40. Zitvogel L, Mayordomo J, Tjandrawan T, DeLeo A, Clarke M, Lotze M, Storkus W (1996) Therapy of murine tumors with tumor-peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97